Palliative chemotherapy in carcinoma nasopharynx.
Chemotherapy
Quality-adjusted Time without Symptoms or Toxicity
nasopharynx
palliative
systemic
Journal
South Asian journal of cancer
ISSN: 2278-330X
Titre abrégé: South Asian J Cancer
Pays: India
ID NLM: 101618774
Informations de publication
Date de publication:
Historique:
entrez:
7
9
2019
pubmed:
7
9
2019
medline:
7
9
2019
Statut:
ppublish
Résumé
Nasopharyngeal carcinoma is a rare malignancy. We conducted an audit of systemic therapies received in palliative setting in carcinoma nasopharynx and studied their outcomes. Patients who underwent first-line palliative systemic chemotherapy between January 2014 and April 2017 for carcinoma nasopharynx at the department of medical oncology at authors' institute were selected for this analysis. Toxicities, responses, progression-free survival (PFS), and overall survival (OS) were analyzed. In addition, a Quality-Adjusted Time without Symptoms or Toxicity analysis with threshold utility analysis was performed. Fifty-one patients were included in this analysis. The indication of palliative chemotherapy was locoregionally recurrent disease in 25 (49.0%) patients and metastatic disease in 26 (51.0%) patients. The overall response rate was 62.0% ( Systemic cytotoxic therapy in nasopharyngeal cancers is associated with high response rates and clinically meaningful PFS; with low duration of time spent in adverse events.
Identifiants
pubmed: 31489292
doi: 10.4103/sajc.sajc_230_18
pii: SAJC-8-173
pmc: PMC6699237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
173-177Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Ann Oncol. 1999 Apr;10(4):421-5
pubmed: 10370784
Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):901-5
pubmed: 10571196
J Clin Oncol. 2001 Mar 1;19(5):1350-7
pubmed: 11230478
Ann Oncol. 2002 Jan;13(1):150-6
pubmed: 11865813
J Clin Oncol. 2002 Apr 15;20(8):2038-44
pubmed: 11956263
Cancer. 2002 Dec 15;95(12):2516-23
pubmed: 12467065
J Clin Oncol. 2004 Nov 15;22(22):4604-12
pubmed: 15542811
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):63-71
pubmed: 16226395
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
J Clin Oncol. 2009 Aug 1;27(22):3684-90
pubmed: 19564532
Ann Oncol. 2011 Mar;22(3):718-22
pubmed: 20716628
Chin J Cancer. 2011 Feb;30(2):106-13
pubmed: 21272442
Head Neck. 2012 Sep;34(9):1225-30
pubmed: 22076785
Lancet Oncol. 2012 Feb;13(2):163-71
pubmed: 22154591
Radiother Oncol. 2014 Mar;110(3):398-403
pubmed: 24231245
J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856
pubmed: 26150579
J Clin Oncol. 2015 Oct 10;33(29):3356-64
pubmed: 26351355
Comput Methods Programs Biomed. 2016 Mar;125:79-87
pubmed: 26652976
Cancer Lett. 2016 Apr 28;374(1):22-30
pubmed: 26828135
Lancet Oncol. 2016 May;17(5):663-70
pubmed: 27083333
Ann Oncol. 2016 Aug;27(8):1633-8
pubmed: 27217543
Lancet. 2016 Oct 15;388(10054):1883-1892
pubmed: 27567279
Lancet Oncol. 2016 Nov;17(11):1509-1520
pubmed: 27686945
Eur J Cancer. 2017 Apr;75:14-23
pubmed: 28214653
Eur J Cancer. 2017 Apr;75:150-158
pubmed: 28235726
Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9
pubmed: 8655368
Kaohsiung J Med Sci. 1996 Apr;12(4):229-34
pubmed: 8683644
J Clin Oncol. 1998 Apr;16(4):1310-7
pubmed: 9552031
J Clin Oncol. 1998 Jul;16(7):2514-21
pubmed: 9667272